A Phase II Study to Evaluate the Imaging Potential of 68GaNOTA-Anti-MMR VHH2 for in Vivo Imaging of MMR-expressing Macrophages by Means of Positron Emission Tomography (PET) in Patients With Non-small Cell Lung Cancer (NSCLC)
Key facts
- Where
- Jette, BelgiumSee the site
- Phase
- 2. fázis
Where in Belgium
- UZ BrusselJette, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- UZ Brussel
- Trial code
- EU 2024-514138-19-00
- Record updated
- 2026. július 29.
- Original description
To correlate the uptake of 68GaNOTA-AntiMMR-VHH2 in a NSCLC lesion before surgery with the immunohistological MMR-staining of the excised lesion.Read full original descriptionShow less
A phase II study to evaluate the imaging potential of 68GaNOTA-Anti-MMR VHH2 for in vivo imaging of MMR-expressing Macrophages by means of Positron Emission Tomography (PET) in patients with non-small cell lung cancer (NSCLC).
To correlate the uptake of 68GaNOTA-AntiMMR-VHH2 in a NSCLC lesion before surgery with the immunohistological MMR-staining of the excised lesion.
Inclusion: Patients who have given informed consent; Patients at least 18 years old; Patient with local, locally advanced or metastatic disease of lung cancer, who is planned for resection or surgical biopsy of at least one lesion. In order to minimise partial volume effect, the diameter of the tumour to be resected or biopsied should be ≥ 10 mm in short axis for invaded adenopathies and ≥ 10 mm in long axis for all other types of lesions; Patients who participated already in this study can be included if the subject meets all of the inclusion and none of the exclusion criteria at time of second inclusion.
Exclusion: Patients at increased risk of death from a pre-existing concurrent illness; Patients with any serious active infection; Patients who have any other life-threatening illness or organ system dysfunction, which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety of the test radiopharmaceutical; Eastern Cooperative Oncology Group (ECOG) performance status 3 or higher; Pregnant patients; Breast feeding patients; Patients who are unlikely to cooperate with the requirements of the study; Patients who are unwilling and/or unable to give informed consent.